The trial is taking place at:
U

University of Wisconsin | Department of Ophthalmology and Visual Sciences - Clinical Eye Research Unit

Veeva-enabled site

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

I

Ideaya Biosciences

Status and phase

Enrolling
Phase 1

Conditions

Breast Cancer
Pancreas Cancer
Ovarian Cancer
Advanced or Metastatic Solid Tumors
Prostate Cancer

Treatments

Drug: IDE-161

Study type

Interventional

Funder types

Industry

Identifiers

NCT05787587
IDE161-001

Details and patient eligibility

About

The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161.

Full description

The purpose of this study is to characterize the safety, tolerability including determination of maximum tolerated dose (MTD), maximum accepted dose (MAD), recommended dose(s) for expansion (RDE) and/or recommended Phase 2 dose (RP2D), pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of IDE161 as a single agent in participants with advanced or metastatic solid tumors harboring BRCA1/2 loss of function alterations and/or other defects in the homologous recombination (HR) pathway.

Enrollment

68 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

1. Adult participants must be 18 years of age or older 2. Advanced or metastatic solid tumors excluding primary central nervous system (CNS) tumors 3. Have documented evidence of genetic alterations conferring homologous recombination deficiency 4. Participant must have progressed on at least one prior line of therapy in the advanced or metastatic setting that is considered an appropriate standard of care, or for which the participant has documented intolerance

Exclusion criteria

1. Known primary CNS malignancy 2. Impairment of GI function or GI disease that may significantly alter the absorption of IDE161 3. Have active, uncontrolled infection 4. Clinically significant cardiac abnormalities 5. Major surgery within 4 weeks prior to enrollment 6. Radiation therapy within 2 weeks prior to enrollment 7. Systemic cytotoxic chemotherapy within 4 weeks prior to enrollment 8. Radioimmunotherapy within 6 weeks of enrollment 9. Treatment with a therapeutic antibody within 4 weeks prior to enrollment 10. Treatment with an anti-cancer small molecule within 5 half-lives (t1/2), or 2 weeks, whichever is shorter

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Sequential Assignment

Masking

None (Open label)

68 participants in 2 patient groups

Module 1 Part 1: Monotherapy Dose Escalation
Experimental group
Description:
Participants will be assigned to a dose level.
Treatment:
Drug: IDE-161
Module 1 Part 2: Monotherapy Dose Expansion
Experimental group
Description:
After a dose is decided in Part 1, participants entering part 2 will be assigned to a dose level.
Treatment:
Drug: IDE-161

Trial contacts and locations

24

Loading...

Central trial contact

IDEAYA Clinical Trials

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems